More Quality Problems at Johnson & Johnson (Odious Details Omitted)

Johnson & Johnson (JNJ), which has been dealing with a long series of quality problems in its over-the-counter drug and other operations – recalled 157,000 surgical staplers, used in hemorrhoid treatment, after the Food and Drug Administration issued a severe safety warnings on the products.

We’ll spare you the details, uh, richly reported by the Wall Street Journal.

J&J’s diversification – it’s relatively less reliant on pharmaceuticals than many of its more narrowly-focused competitors, as in Pfizer (PFE), Merck (MRK), Novartis (NVS) and GlaxoSmithKline (GSK) -- is among the factors that has given it a higher valuation, based on PE ratio. But the complexity seems rather hard to manage.

JNJ PE Ratio TTM Chart

JNJ PE Ratio TTM data by YCharts

From the editors of YCharts, which includes the just-released YCharts Pro Platinum for professional investors.


Start your free 7-Day Trial.

{{}} No credit card required.

Already a subscriber? Sign in.